Search results
France bags $16 billion investment boost from Microsoft, Pfizer and others as President Emmanuel...
Fortune· 4 days agoOfficials announced today that the country has bagged €15 billion ($16.2 billion) in investments from multinational companies ranging from tech to pharmaceuticals, helping ...
Biotech Behemoths: 3 Giants Set to Dominate the Health Scene
InvestorPlace· 3 days agoBiotechnology is an interesting place to look if you’re looking for growth and are not put off by...
Moderna (MRNA) Falls as FDA Extends Review Time for RSV Vaccine
Zacks via Yahoo Finance· 3 days agoCDC has also recommended the use of both GSK and Pfizer’s RSV vaccines for older adults. GSK’s...
Novavax shares soar on license deal with Sanofi at lofty valuation
Reuters· 4 days ago, opens new tab for its COVID-19 vaccine in exchange for a stake that valued the U.S. biotech firm...
Novavax signs multibillion-dollar deal with Sanofi to commercialize Covid vaccine, develop...
CNBC· 7 days agoA health worker prepares a dose of the Novavax vaccine as the Dutch Health Service Organization...
JD Supra: California Jury Stamps Its Approval on SEC’s Novel Shadow Trading Theory
JD Supra· 5 days agoUnder a civil misappropriation theory of insider trading, the jury found by a preponderance of the evidence that Matthew Panuwat used inside information about the potential purchase of his company ...
Unveiling Viatris (VTRS)'s Value: Is It Really Priced Right? A C
Guru Focus· 2 days agoWith a Loss Per Share of 0.06, the question arises: is Viatris modestly overvalued? This article delves into a detailed valuation analysis to help investors make informed decisions. Viatris ...
Spectral AI, Inc. (NASDAQ:MDAI) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 4 days agoSpectral AI, Inc. (NASDAQ:MDAI) Q1 2024 Earnings Call Transcript May 11, 2024 Spectral AI, Inc....
American exceptionalism on full display in financial markets … or is it?
The Washington Times· 2 days agoThe U.S. economy has confounded forecasters’ dour predictions, but not the optimism of financial...
Moderna (MRNA) Falls as FDA Extends Review Time for RSV Vaccine
Zacks· 4 days agoFree Report) were down 4.4% on May 10 after the company announced that the FDA has delayed the review timeline for its mRNA-based, respiratory syncytial virus (RSV) vaccine, mRNA-1345. Moderna ...